Anavex Life Sciences (AVXL) Convertible Debt (2014)
Anavex Life Sciences (AVXL) reported Convertible Debt of $1091.0 for Q2 2014, up 7.91% sequentially from $1011.0 in Q1 2014.
Anavex Life Sciences (AVXL) Convertible Debt (2014) Analysis & Trends
Anavex Life Sciences (AVXL) has 1 years of Convertible Debt data on file, last reported at $1091.0 in Q2 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Anavex Life Sciences | 229.83 Mn | 98.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2014 | 1,091.00 |
| Mar 31, 2014 | 1,011.00 |